Optical imaging of primary and regional melanoma to guide surgical resection

描述(申请人提供)：黑色素瘤的主要治疗方法仍然是手术切除，切缘阴性。不幸的是，黑色素瘤的边缘无法显示或触诊；因此，外科医生根据肿瘤组织学和穿透深度获得了健康的外观组织的广泛边缘。未能改善手术治疗导致未能提高这种疾病的存活率，而大多数其他类型的癌症在同一时期显示出显著的存活率提高。提高黑色素瘤的存活率有赖于改善初级治疗方式。我们建议确定FDA批准的针对通常表达的黑色素瘤抗原的抗体是否可以用于显微边缘和区域性疾病的成像。我们建议确定成像的最佳抗体(或组合)，这项技术的敏感性和特异性，以及它促进肿瘤荧光的机制。使用这一策略，可以选择性地获得组织学边缘，并保留正常组织。如果成功，这种技术将极大地影响手术切除的方式。

DESCRIPTION (provided by applicant): Primary treatment for melanoma remains surgical excision with negative margins. Unfortunately, melanoma margins cannot be visualized or palpated; as a result surgeons obtain wide margins of healthy appearing tissue based on tumor histology and depth of penetration. Failure to improve surgical cures contributes to a failure to improve survival in this disease while most other cancer types have shown dramatically improved survival over the same time period. Improving melanoma survival depends on improving the primary treatment modality. We propose to determine if FDA approved antibodies to commonly expressed melanoma antigens can be leveraged for imaging of microscopic margins and regional disease. We propose to identify the optimal antibody (or combinations) for imaging, the sensitivity and specificity of this technique and the mechanisms by which it promotes fluorescence in the tumor. Using this strategy, histological margins can be selectively obtained and normal tissues spared. If successful such a technique would dramatically impact how surgical resections are performed.